A carregar...
MK-1775, a potent Wee1 inhibitor, synergizes with gemcitabine to achieve tumor regressions, selectively in p53-deficient pancreatic cancer xenografts
PURPOSE: Investigate the efficacy and pharmacodynamic effects of MK-1775, a potent Wee1 inhibitor, in both monotherapy and in combination with gemcitabine using a panel of p53-deficient and p53-wild type human pancreatic cancer xenografts. EXPERIMENTAL DESIGN: Nine individual patient-derived pancrea...
Na minha lista:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2011
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3307341/ https://ncbi.nlm.nih.gov/pubmed/21389100 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-10-2580 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|